GlassScriptPhysician profile
Sung Ho Lee
NPI 1841426780
$10,914.02
in general payments reported to CMS, 2019-2025
71 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,823 · 2020: $1,527 · 2021: $628 · 2022: $593 · 2023: $795 · 2024: $1,288 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,024 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.78 |
| Education | $320.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,266.85 | 2019-2021 | |
| Janssen Biotech, INC. | $1,009.57 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $744.79 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Pfizer INC. | $603.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $511.64 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $485.35 | 2020-2025 | |
| Eisai INC. | $424.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $395.68 | 2019-2025 | Opdivo, Eliquis |
| Novartis Pharmaceuticals Corporation | $384.73 | 2025 | |
| Genentech USA, INC. | $379.24 | 2019-2025 | Polivy |
| Pharmacyclics LLC, An Abbvie Company | $335.54 | 2019-2023 | Imbruvica, Epkinly |
| Shockwave Medical, INC | $322.50 | 2021-2022 | |
| Glaxosmithkline, LLC. | $250.69 | 2023-2025 | Ojjaara, Jemperli, Blenrep |
| Ipsen Biopharmaceuticals, INC | $234.30 | 2023-2025 | Onivyde, Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $216.66 | 2019-2025 | Fruzaqla, Iclusig |
Show all 66 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sung Ho Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.